Page Image

The Uromigos

The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.


Latest Episode

Episode 310: Dosing and Duration of Drugs From a Cost Perspective
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune checkpoint inhibitors. Dr. Goldstein is a Senior Physician at the Davidoff Cancer Center of Rabin Medical Center, and serves as Senior Lecturer at Tel Aviv University. ...

The Uromigos: Live & Unplugged 2023

Kidney Cancer Discussions

Dr. Brian Rini’s Disclosures

Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis

Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai

Stock: PTC therapeutics

Get updates from The Uromigos straight to your inbox.